Paushak Limited manufactures specialty chemicals and pharmaceutical intermediates used in industrial and healthcare applications. Its specialized product portfolio provides exposure to higher-value chemical markets. Growth in pharmaceuticals and specialty chemical applications can provide opportunities. Raw-material costs, product demand, environmental regulations, capacity utilization, pricing and competition remain important factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|
| ₹1,675 cr | ₹277 cr | ₹47 cr | 35.4 | 19.18 | 3.24 | 8.6% | 0.13 | ₹-34 cr | 28.8 | 1.56 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Sep 2026 | 89 | 14 | 5.48 | — | — | 15.1% |
| Jun 2026 | 84 | 15 | 6.13 | — | — | 18.1% |
| Mar 2026 | 55 | 12 | 5.07 | — | — | 22.7% |
| Dec 2025 | 49 | 6 | 2.50 | — | — | 12.6% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | — Not assessable |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | — Not assessable |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | — Not assessable |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Turtle | ✗ Close above the prior 55-session high · 881.95 ✗ Close above the prior 20-session high · 881.95 ✗ Close below the prior 20-session low · 634.00 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| Graham | ✗ Price at or below the Graham number · Graham number 300.83 ✗ P/E 15 or less · P/E 35.4 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 3.24 ✓ Current ratio 2 or more · 2.37 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 44/100 | Expensive |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAUSHAKLTD this stock | -5.2 | +20.1 | +37.4 | — | — | — | 35.4 | 3.24 | 8.6 | — | — | 0.13 | 28.8 | 1,675 | 277 | 47 | 19.2 | 1.56 |
| BODALCHEM | -14.3 | +149.1 | +142.6 | +175.9 | +104.7 | +20.3 | 30.1 | 1.78 | 4.2 | 6.7 | — | 0.69 | 14.2 | 2,065 | 2,267 | 69 | 5.5 | 0.70 |
| RPEL | +7.6 | +38.6 | +149.7 | +161.5 | — | — | 115.8 | 28.99 | 25.0 | 31.2 | — | 0.02 | 85.7 | 8,164 | 315 | 70 | 15.3 | 1.42 |
| FCL | -2.1 | +41.7 | +142.9 | +128.2 | +70.0 | +356.5 | 43.9 | 7.36 | 13.5 | 18.3 | — | 0.01 | 39.5 | 6,499 | 1,012 | 148 | 1.3 | 1.46 |
| AETHER | -6.7 | +4.9 | +28.3 | +104.1 | +70.3 | — | 85.6 | 8.22 | 9.4 | 11.6 | — | 0.18 | 55.5 | 20,191 | 1,224 | 235 | 17.8 | 0.75 |
| KRISHANA | +18.3 | +46.5 | +66.7 | +87.6 | +322.8 | +1076.5 | 33.5 | 11.74 | 38.1 | 27.3 | — | 1.31 | 22.8 | 6,581 | 2,555 | 197 | 6.4 | 1.04 |
| OAL | +21.4 | +78.0 | +98.3 | +85.2 | +69.9 | -28.9 | 395.2 | 3.16 | 0.5 | 4.5 | — | 0.61 | 32.3 | 2,101 | 1,065 | 5 | 1.6 | 0.97 |
| NEOGEN | -0.3 | +13.7 | +66.1 | +70.0 | +43.2 | +81.2 | 186.7 | 8.32 | 3.6 | 6.6 | — | 1.63 | 56.6 | 6,795 | 926 | 36 | 13.3 | 0.84 |
| NAVINFLUOR | -5.1 | +3.7 | +26.0 | +59.6 | +123.5 | +111.1 | 52.9 | 10.52 | 20.1 | 21.4 | — | 0.31 | 37.8 | 41,822 | 3,634 | 790 | 154.2 | 0.78 |
| VALIANTORG | +9.1 | +74.3 | +72.0 | +59.4 | -0.5 | -70.1 | 24.0 | 1.72 | 4.5 | 6.2 | — | 0.33 | 15.5 | 1,305 | 766 | 54 | 19.4 | 1.02 |
| ICIL | -5.3 | +8.0 | +58.0 | +58.8 | +74.0 | +46.7 | 55.6 | 3.56 | 5.5 | 8.7 | — | 0.46 | 21.0 | 8,394 | 4,390 | 151 | 7.6 | 1.50 |